Keros Therapeutics, Inc. (KROS) has experienced a notable downturn, touching a 52-week low of $15.31. This latest price level reflects a significant drop from previous valuations, marking a challenging period for the biotechnology company with a current market capitalization of $628 million. InvestingPro analysis indicates the stock is in oversold territory, with a strong liquidity position reflected in its current ratio of 19.03. Over the past year, Keros Therapeutics has seen its stock value decrease by a staggering 69.9%, indicating a tough market environment and potential investor concerns over the company's performance and future prospects. This decline to a 52-week low could attract the attention of value investors looking for potential rebounds or signal caution to those wary of continued volatility. According to InvestingPro, four analysts have recently revised their earnings upwards for the upcoming period, and the company maintains more cash than debt on its balance sheet. Discover 14 additional exclusive insights available on InvestingPro.
In other recent news, Keros Therapeutics has faced a series of significant adjustments in its stock ratings and price targets. Analyst firm Truist Securities maintained a Buy rating but reduced the price target from $100 to $43, while Oppenheimer lowered its price target to $63 but maintained an Outperform rating. Similarly, H.C. Wainwright kept a Buy rating but lowered the price target from $100 to $47. Jefferies also reduced its price target to $23 but retained its Buy rating. On the other hand, TD Cowen and BTIG downgraded their ratings from Buy to Hold and Neutral, respectively.
These adjustments come after Keros Therapeutics halted dosing in the mid-to-high dose cohorts of its Phase 2 TROPOS study for the drug cibotercept due to challenges differentiating its efficacy and safety profile. Despite this, the company has entered a substantial licensing agreement with Takeda Pharmaceutical (TADAWUL:2070) Company (NYSE:TAK) for the development of elritercept, which could potentially provide over $2 billion in opportunities.
Furthermore, Keros Therapeutics recently completed patient enrollment for its Phase 2 TROPOS trial and appointed Dr. Yung H. Chyung as its new Chief Medical (TASE:PMCN) Officer. The company also anticipates topline data for all treatment arms in the second quarter of 2025. These are recent developments that investors should consider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.